Navigation Links
Stanford researchers first to turn normal cells into 3-D cancers in tissue culture dishes
Date:11/21/2010

STANFORD, Calif. Researchers at the Stanford University School of Medicine have successfully transformed normal human tissue into three-dimensional cancers in a tissue culture dish for the first time. Watching how the cells behave as they divide and invade surrounding tissue will help physicians better understand how human cancers act in the body. The new technique also provides a way to quickly and cheaply test anti-cancer drugs without requiring laboratory animals.

"Studies of this type, which used to take months in animal models, can now occur on a time scale of days," said Paul Khavari, MD, PhD, the Carl J. Herzog Professor and chair of dermatology at Stanford. The researchers focused on epithelial cells, which line the surfaces and cavities of the body. Cancers of epithelial cells make up approximately 90 percent of all human cancers.

The study of three-dimensional tumors also avoids the use of cancer cell lines, which are typically grown in single layers and may have accumulated genetic changes that don't accurately reflect what happens in humans.

Khavari, who is also a member of the Stanford Cancer Center and serves as dermatology service chief at the Veterans Affairs Palo Alto Health Care System, is the senior author of the research, which will be published online Nov. 21 in Nature Medicine. Todd Ridky, MD, PhD, a former postdoctoral scholar in Khavari's laboratory, is the first author. Ridky is now an assistant professor at the University of Pennsylvania.

The researchers worked with normal human epithelial cells gathered from surgical samples from skin, cervix, esophagus and throat. Unlike cancer cell lines, some of which have been grown in laboratories around the world for years, these primary cells were minimally cultured.

To make these normal cells cancerous, the researchers used viruses to tweak just two genetic pathways known to be involved in uncontrolled growth. One drives cells forward in the cell cycle while the other disables an internal checkpoint that normally blocks abnormal proliferation. Many naturally occurring human cancers display identical genetic changes, and the researchers found that simultaneously altering the two pathways is highly effective at transforming normal cells.

Khavari and Ridky then added the altered, pre-cancerous epithelial cells to a tissue culture dish containing other components of human skin. Epithelial cells normally sit on a thin partition called the basement membrane that separates them from a lower layer of skin called the stroma. They found that at first the cells nestled down on the basement membrane and formed what looked like a normal, three-dimensional cross-section of skin. But within about six days, the cells started to behave more ominously punching through the membrane and invading the stromal tissue below.

"This reflects what we see happening in spontaneous human tumors," said Khavari. "Cells go from a pre-malignant state to invasive cancers, often over the course of years. Only in this intact, human-tissue model it occurs much more quickly." In contrast, unaltered cells remained obediently on their side of the basement membrane.

When the researchers examined the patterns of gene expression in the newly cancerous cells, they found that the patterns closely matched the genetic profiles of spontaneously occurring human cancers. But when the cells were grown in a single layer, without the basement membrane, stroma and normal three-dimensional tissue structure, their gene expression profiles were markedly different.

"This tells us that conclusions drawn from studying cells grown in two-dimensional culture need to be correlated with other findings to help ensure clinical relevance," said Khavari.

The researchers took advantage of their new "tumor-in-a-dish" model to test 20 new experimental anti-cancer drugs. Many of these drugs cannot be easily tested in animals because they are difficult to administer and may be toxic in their current form. But Khavari and Ridky were able to quickly home in on three promising candidates that stopped the altered epithelial cells from invading through the membrane. While the drugs will still have to be optimized for testing in animals, this type of pre-screening allows researchers to narrow down the possibilities.

The three-dimensional culture system also indicated that the stromal cells themselves somehow encourage the invasion of the altered epithelial cells, and that the cells don't need to be dividing wildly in order to be able to invade.

"These things had never been directly tested before in human tissue," said Khavari, who pointed out that the new model still doesn't incorporate many other biological players, such as the immune system and an active metabolism. And yet "now that we can create human tumors from multiple different human tissues, we have a new way to assess what might be going on in spontaneous human tumors."


'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Related medicine news :

1. Certain cancer therapies success depends on presence of immune cell, Stanford study shows in mice
2. Need a study break to refresh? Maybe not, say Stanford researchers
3. Stanford-led study disproves link between genetic variant, risk of coronary artery disease
4. Wider statin use could be cost-effective preventive measure, Stanford study finds
5. Preventive care poses dilemma for emergency departments, Stanford study finds
6. New treatment for severe aortic stenosis shown to save lives, Stanford researchers say
7. Arsenic shows promise as cancer treatment, Stanford study finds
8. Stanford Who's Who & Anthony Casimano Make Donation to Help Support National Organization, CancerCare
9. Melanoma-initiating cell identified by Stanford scientists
10. Pro Ana Versus Pro Recovery Sites: New Study by Johns Hopkins and Stanford University raises concerns.
11. Orphaned elderly serious casualty of African AIDS epidemic, Stanford study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... ALLENTOWN , Pa. and KALAMAZOO, Mich. ... Allentown, Penn. , and OptiMed Specialty Pharmacy ... a business partnership to offer a strategic hub service ... PMD Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, ... A spirometer is a medical device used ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology: